• news.cision.com/
  • Implantica/
  • Implantica announces its intention to launch an initial public offering of Swedish Depository Receipts on Nasdaq First North Premier Growth Market in Stockholm

Implantica announces its intention to launch an initial public offering of Swedish Depository Receipts on Nasdaq First North Premier Growth Market in Stockholm

Report this content


Implantica AG[1] (“Implantica” or the “Company”), a medtech group with operations within the implantable medical device and eHealth markets, today announces its intention to launch an initial public offering of Swedish Depository Receipts (“SDRs”) on Nasdaq First North Premier Growth Market in Stockholm. The offering is expected to include new SDRs, representing newly issued Class A shares in Implantica (the “Offering”). Swedbank Robur Ny Teknik, Handelsbanken Fonder, TIN Fonder, Skandia and Nordea Asset Management (together the “Cornerstone Investors”) have undertaken to subscribe for SDRs corresponding to a total value of SEK 800 million.

The Offering in brief:

  • The Offering is expected to be conducted at a fixed price of SEK 65.00 per SDR, corresponding to a total market value of the Company's shares of approximately SEK 2,925 million prior to the Offering.
  • One (1) SDR represents one (1) underlying Class A share in the Company. The Company has two share classes, Class A and Class B shares.
  • The Offering includes new SDRs, representing newly issued Class A shares, that is expected to generate approximately SEK 1,100 million in proceeds to the Company before deduction of costs relating to the Offering.
  • In order to cover a potential overallotment in connection with the Offering, the Company has, at the request of the Sole Global Coordinator and Bookrunner, committed to issue additional new SDRs, corresponding to a maximum of 15 percent of the number of SDRs in the Offering (the “Overallotment Option”).
  • Provided that the Overallotment Option is exercised in full, the Offering is expected to amount to approximately SEK 1,265 million, corresponding to approximately 30.2 percent of the share capital and 17.8 percent of the votes in the Company after the Offering.
  • Prior to the Offering, the five Cornerstone Investors have undertaken to subscribe for SDRs under certain conditions, and at the same price as other investors, corresponding to a total value of SEK 800 million or approximately 63 percent of the Offering, including the Overallotment Option. The five Cornerstone Investors’ commitments are distributed as follows:
    • Swedbank Robur Ny Teknik: SEK 250 million
    • Handelsbanken Fonder on behalf of managed funds: SEK 200 million
    • TIN Fonder: SEK 150 million
    • Skandia: SEK 100 million
    • Nordea Asset Management on behalf of, amongst others, the fund Nordea Innovation Stars: SEK 100 million
  • Full terms and conditions for the Offering will be available in a prospectus, which is expected to be published on or about 7 September 2020.
  • The Offering is directed to institutional investors in Sweden and internationally as well as to the general public in Sweden.
  • First day of trading in the Company's SDRs on Nasdaq First North Premier Growth market is expected to commence on or about 21 September 2020.

About Implantica and background to the Offering

Implantica is a medtech group with operations within the implantable medical device and eHealth markets. The Company’s lead product RefluxStopTM is a passive CE-marked implant for prevention of gastroesophageal reflux. Current surgical gastroesophageal reflux disease ("GERD") treatments function by compressing the food passageway, giving rise to various adverse complications. RefluxStopTM has a completely different design thesis, which achieves better results without the complications associated with existing surgical GERD treatments. The Company believes RefluxStopTM has the potential to spur a paradigm shift in GERD treatments. In addition to

RefluxStopTM, the Company has an extensive product pipeline that is expected to further support Implantica’s growth in the coming years.

The Group was founded in 2015 by Dr. Peter Forsell, principal shareholder and Chief Executive Officer (CEO), by injecting two platform technologies at cost as well as products and patents. It took eight years to develop the platform technologies, the wireless energising and eHealth platforms, and after scanning the whole body for suitable product applications, a large patent portfolio of over 1,000 patent cases was created. During a three-year period over 70 engineers analysed over 300 individual inventions, conducting market and product analysis and prototyping to select 40 viable implant product candidates. This brings a platform for further long-term growth potential, however, in addition to the commercialisation of RefluxStopTM, which is already on the market, the company is strictly focusing on launching three more products, UriControl®, UriRestore® and AppetiteControl.   

At their previous company, Dr. Forsell and Stephan Siegenthaler, Chief Sales & Marketing Officer, were co-founders and executive management members of Obtech Medical AG (“Obtech”) that brought the Swedish Adjustable Gastric Band (“SAGB”) – an innovative gastric band developed by Dr. Forsell – to market. In 2002 Obtech was sold to Johnson & Johnson for CHF 175 million before US FDA approval. Since the sale of Obtech, Dr. Forsell has injected over EUR 85.4 million in Implantica.

Implantica’s board of directors believes the Company has a promising future with the CE-marked RefluxStopTM under commercialization, an attractive product pipeline and substantial revenue potential.

To successfully commercialize RefluxStopTM as well as further develop and commercialize UriControl®, UriRestore® and AppetiteControlTM, the board of directors views the Offering as the logical next step to further support the Company’s strategy and development. The board of directors believes that the initial public offering of Implantica’s SDRs on Nasdaq First North Premier Growth Market will, amongst other things:

  • finance Implantica’s further growth;
  • broaden and strengthen Implantica’s shareholder base and offer a liquid market for its SDRs; and
  • strengthen Implantica’s recognition and brand among patients, surgeons, investors and the sector in general.

Dr. Peter Forsell, CEO, Founder and principal shareholder, comments:

"We are happy to announce the intended listing of Implantica on Nasdaq First North Premier and are pleased to announce the strong support of the cornerstone investors. This is an important milestone for the Group and will provide us with a great platform to reach our goals. Based on superior clinical trial results, our first product RefluxStop™ is a potential paradigm shift in acid reflux treatment, a condition impacting 17% of the European population on a weekly basis. RefluxStop™ restores natural anatomy and avoids many of the side-effects common in current treatments and is under commercialisation.”

Liselott Kilaas, Chairman of the Board, comments:

Implantica has a very experienced and dedicated leadership team and innovative and very promising medical products and solutions based on years of research and experience. We have ambitious plans for the company’s future, and the money raised from this listing will help us ramp up our efforts to get these products to the market where they can make a substantial difference to people in need."

Prospectus and application forms

A prospectus, containing complete terms and conditions of the Offering is expected to be made public on or about 7 September 2020 on Implantica's website (www.Implantica.com) and Pareto Securities’ website (www.paretosec.com). Application forms will be made available on Pareto Securities’ website when the subscription period has commenced. Applications can also be made through the Aktieinvest's website (www.aktieinvest.se) and Avanza's website (www.avanza.se).


Pareto Securities is the Global Coordinator and Sole Bookrunner in the Offering. Baker McKenzie is the legal advisor to Implantica as to Swedish and Swiss law and Roschier is the legal advisor to Pareto Securities in the Offering.

For further information, please contact:

Nicole Pehrsson, Investor Relations, Implantica

Telephone (CH): +41 (0)79 335 09 49

E-mail: nicole.pehrsson@implantica.com


The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Implantica in any jurisdiction, neither from Implantica nor from someone else.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. A prospectus in connection with the Offering will be prepared and published by the Company after it has been scrutinized and approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. Pareto Securities is acting for Implantica in connection with the Offering and no one else and will not be responsible to anyone other than Implantica for providing the protections afforded to its clients nor for giving advice in relation to the Offering or any other matter referred to herein.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the Unites States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq First North Premier Growth Market rule book for issuers.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the SDRs in Implantica have been subject to a product approval process, which has determined that the SDRs are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “Target Market Assessment”). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the SDRs in Implantica may decline and investors could lose all or part of their investment; the SDRs in Implantica offer no guaranteed income and no capital protection; and an investment in the SDRs in Implantica is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the SDRs in Implantica.

Each distributor is responsible for undertaking its own target market assessment in respect of the SDRs in Implantica and determining appropriate distribution channels.


[1] Implantica AG is a Liechtenstein limited liability company.